Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.

Ying LiuJacquelyn BainbridgeStefan SillauSarah N Fischer Michelle Adkins Christopher H Domen John A ThompsonTristan SeawaltJost Klawitter Cristina SempioGrace ChinLisa FormanMichelle FullardTrevor HawkinsLauren SeebergerHeike NewmanDavid VuMaureen Anne Leehey

Published in: Movement disorders : official journal of the Movement Disorder Society (2024)

The brief duration and strong placebo response limits interpretation of effects, but there was no benefit, perhaps worsened cognition and sleep, and there was many mild adverse events. Longer duration high quality trials that monitor cannabinoid concentrations are essential and would require improved availability of research cannabinoid products in the United States. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

physical activity
sleep quality
double blind
clinical trial
randomized controlled trial
depressive symptoms
meta analyses
placebo controlled